Team:Washington/Gram Negative/Build

From 2010.igem.org

(Difference between revisions)
(SubHeader 2)
Line 28: Line 28:
=Header 1=
=Header 1=
-
==SubHeader 2==
+
==Why induce tse2 expression only when a gram-negative pathogen is present?==
-
 
+
      A type six secretion system +/Tse2 + strain of ''E. coli'' could be administered like a traditional antibiotic after a pathogen infection by having a strain that constitutively expresses Tse2 and Tsi2. However, this would be a fairly brute force method of anti-bacterial comparable to traditional chemical antibiotics in its damage to the gut’s natural flora, and is only advantage over chemical antibiotics would be the current lack of Tse2 resistant pathogenic bacterial strains. If Tse2 expression is induced by a chemical signal  indicative of the presence of a pathogen, any unintended disruption of the natural gut flora will be limited to the area infected with pathogens, and the risk of Tse2 resistance would decrease.
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS---------------------------------------->
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS---------------------------------------->

Revision as of 06:19, 7 September 2010

Header 1

Why induce tse2 expression only when a gram-negative pathogen is present?

     A type six secretion system +/Tse2 + strain of E. coli could be administered like a traditional antibiotic after a pathogen infection by having a strain that constitutively expresses Tse2 and Tsi2. However, this would be a fairly brute force method of anti-bacterial comparable to traditional chemical antibiotics in its damage to the gut’s natural flora, and is only advantage over chemical antibiotics would be the current lack of Tse2 resistant pathogenic bacterial strains. If Tse2 expression is induced by a chemical signal  indicative of the presence of a pathogen, any unintended disruption of the natural gut flora will be limited to the area infected with pathogens, and the risk of Tse2 resistance would decrease.

Designing the Gram(-) Therapeutic       Testing the Gram(-) Therapeutic